Ajulemic acid

Drug Profile

Ajulemic acid

Alternative Names: Anabasum; CPL-7075; CT-3; DMH-11C; HU-239; IP-751; JBT-101; Resunab

Latest Information Update: 11 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator University of Massachusetts Medical School
  • Developer Cervelo Pharmaceuticals; Corbus Pharmaceuticals; Indevus Pharmaceuticals; National Institute of Arthritis and Musculoskeletal and Skin Diseases; University of Erlangen-Nuremberg; University of Pennsylvania; University of Siena
  • Class Anti-inflammatories; Antiasthmatics; Antirheumatics; Cannabinoids; Non-opioid analgesics; Small molecules
  • Mechanism of Action Cannabinoid receptor CB2 agonists; Interleukin 1 beta inhibitors; Matrix metalloproteinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cystic fibrosis; Systemic scleroderma
  • New Molecular Entity Yes
  • Available For Licensing Yes - Interstitial cystitis

Highest Development Phases

  • Phase II Cystic fibrosis; Dermatomyositis; Systemic scleroderma
  • Phase I Inflammation
  • Preclinical Pulmonary fibrosis
  • Discontinued Interstitial cystitis; Muscle spasticity; Neuropathic pain; Pain; Poisoning

Most Recent Events

  • 07 Aug 2017 New efficacy data from a phase II trial in Systemic scleroderma released by Corbus Pharmaceuticals
  • 01 Jun 2017 Corbus Pharmaceuticals plans a phase IIb trial for Cystic fibrosis in the fourth quarter of 2017
  • 01 Jun 2017 Corbus Pharmaceuticals plans a phase III trial for Systemic scleroderma, in the fourth quarter of 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top